Research suggests that maternal immune activation (MIA) during pregnancy increases the risk of neurodevelopmental disorders including schizophrenia and autism in the offspring. Current theories suggest that inflammatory mediators including cytokines and chemokines may underlie the increased risk of these disorders in humans. For example, elevated maternal interleukin-8 (IL-8) during pregnancy is associated with increased risk of schizophrenia in the offspring. Given this association, the present experiments examined ELR-CXC chemokines CXCL1 and CXCL2, rodent homologues of human IL-8, and activation of their receptors (CXCR1 and CXCR2) in an established rodent model of MIA. Pregnant Long Evans rats were treated with the viral mimetic polyinosinic-polycytidylic acid (polyI:C; 4 mg/kg, i.v.) on gestational day 15. Protein analysis using multiplex assays and ELISA showed that polyI:C significantly increased maternal serum concentrations of interleukin-1β, tumor necrosis factor, and CXCL1 3 h after administration. Subsequent experiments tested the role of elevated maternal CXCL1 on behavior of the offspring by administering a CXCR1/CXCR2 antagonist (G31P; 500 μg/kg, i.p.; 1 h before, 48 and 96 h after polyI:C treatment). The male offspring of dams treated with polyI:C demonstrated subtle impairments in prepulse inhibition (PPI), impaired associative and crossmodal recognition memory, and altered behavioral flexibility in an operant test battery. While G31P did not completely reverse the behavioral impairments caused by polyI:C, it enhanced PPI during adolescence and strategy setshifting and reversal learning during young adulthood. These results suggest that while polyI:C treatment significantly increases maternal CXCL1, elevations of this chemokine are not solely responsible for the effects of polyI:C on the behavior of the offspring.
Introduction
Numerous studies have found evidence that maternal infection during pregnancy increases the offspring's risk of developing neurodevelopmental psychiatric disorders such as schizophrenia and autism (Arias et al., 2012; Ashwood et al., 2011; Patterson, 2009) . Given that a variety of pathogens are associated with increase d risk of psychiatric disorders, exposure of the developing fetus to maternal and/or fetal cytokines released during infection may alter normal development of the nervous system resulting in the behavioral and cognitive symptoms (Fineberg and Ellman, 2013; Gilmore et al., 2004; Watanabe et al., 2010) . Chemokines, a sub-class of cytokines with chemotactic properties (Tran and Miller, 2003) , and their associated G proteincoupled receptors are involved in brain development (Arrode-Bruses and Bruses, 2012; Brown et al., 2004; Cho and Miller, 2002; Deverman and Patterson, 2009; Garay et al., 2013; Ragozzino, 2002) and recent human epidemiological research has uncovered associations between numerous chemokines and neurodevelopmental disorders (Ashwood et al., 2011; Reale et al., 2011; Stuart and Baune, 2014) . One study of a large birth cohort found correlations between elevated maternal serum levels of the chemokine interleukin-8 (IL-8) during pregnancy and: 1) the development of schizophrenia spectrum disorders in adult offspring (Brown et al., 2004) ; 2) structural brain alterations, including increased ventricular and decreased cortical volumes, in schizophrenia patients (Ellman et al., 2010) . These findings strongly suggest that prenatal exposure to maternal immune activation (MIA) alters the offspring's development through a mechanism that is at least partially dependent on IL-8 signaling (Meyer et al., 2011) .
Rodent models of MIA have high validity in terms of the underlying etiology, disease progression, and behavioral symptoms of human disorders including schizophrenia and autism (Meyer and Feldon, 2012;  
